Email this article 
IMMUNE THERAPY INFLUENCE ON a-DEFENSIN LEVEL IN PERIPHERAL BLOOD NEUTROPHILES IN PYODERMIA PATIENTS
- Authors: Tsyvkina EA1, Fedenko ES1, Budikhina AS2, Pinegin BV1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 7, No 6 (2010)
- Pages: 25-30
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/881
- DOI: https://doi.org/10.36691/RJA881
- ID: 881
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Background. The purpose was to investigate a-defensin levels in neutrophiles of pyodermia patients in comparison
with healthy donors, to estimate clinical efficiency of glucosaminyl muramyl dipeptide (Licopid) and its influence on a-defensin levels.
Materials and method. 31 patients with pyodermia and 17 healthy donors were investigated. Intracellular a-defensin
levels in neutrophiles in the peripheral blood were estimated by flow cytometry with mouse anti-NPantibodies (Hy
cult biotechnology). All patients with pyodermia were treated with Licopid 10 mg once a day within 10 days. Clinical
and laboratory results were measured after 7-0 days course of treatment and one month after treatment.
Results. The a-defensin level in patients with pyodermia was reduced in comparison with healthy donors. Immune
therapy with licopid 10 mg once a day as a complex treatment lead to a-defensin level increase in leukocytes
of peripheral blood.
Conclusion. The treatment with licopid 10 mg a day lead to prolonged remission and to increase of endocellular
a-defensin level. Definition of a-defensin levels can be useful for advisability and for selection of immune
therapy in pyodermia patients. Thus, a decrease of a-defensin levels in pyodermia patients, possibly, is a marker
of the chronic bacterial inflammation.
with healthy donors, to estimate clinical efficiency of glucosaminyl muramyl dipeptide (Licopid) and its influence on a-defensin levels.
Materials and method. 31 patients with pyodermia and 17 healthy donors were investigated. Intracellular a-defensin
levels in neutrophiles in the peripheral blood were estimated by flow cytometry with mouse anti-NPantibodies (Hy
cult biotechnology). All patients with pyodermia were treated with Licopid 10 mg once a day within 10 days. Clinical
and laboratory results were measured after 7-0 days course of treatment and one month after treatment.
Results. The a-defensin level in patients with pyodermia was reduced in comparison with healthy donors. Immune
therapy with licopid 10 mg once a day as a complex treatment lead to a-defensin level increase in leukocytes
of peripheral blood.
Conclusion. The treatment with licopid 10 mg a day lead to prolonged remission and to increase of endocellular
a-defensin level. Definition of a-defensin levels can be useful for advisability and for selection of immune
therapy in pyodermia patients. Thus, a decrease of a-defensin levels in pyodermia patients, possibly, is a marker
of the chronic bacterial inflammation.
About the authors
E A Tsyvkina
Institute of ImmunologyInstitute of Immunology
E S Fedenko
Institute of ImmunologyInstitute of Immunology
A S Budikhina
B V Pinegin
Institute of ImmunologyInstitute of Immunology
References
- Караулов А.В., Калюжин О.В. Медикаментозная иммунотерапия. VII Рос. нац. конгр. «Человек и лекарство». Тез. докл. М., 2000, с. 407.
- Catherine M.T. Chronnell, Lucy R. Ghali, Rozina S. Ali et al. Human b-Defensin-1 and -2 Expression in Human Pilosebaceous Units: Upregulation in Acne Vulgaris Lesions. Journal of Investigative Dermatology. 2001, v. 117, p. 1120-1125.
- Yamasaki K., Gallo R.L. Antimicrobial peptides in human skin disease. Eur. J. Dermatol. 2008, v. 18 (1), p. 11-21.
- Philpott M. Defensins and acne. Mol. Immunol. 2003, v. 40 (7), p. 457-462.
- Дьяконова В.А., Пак В.Г., Будихина А.С. и соавт. Оценка функциональной активности фагоцитарной системы человека в норме и при патологии. Пособие для врачей по клинической лабораторной диагностике. М., 2008, с. 29.
- Laube S. Skin infections and ageing. Ageing. Res. Rev. 2004, v. 3, p. 69-89.
- Ващенко Е.В. Клиническая значимость оценки функциональной активности лейкоцитов у больных с хронической рецидивирующей пиодермией. Диссертация канд. мед. наук. М., 2008.
- Cole A.M. Antimicrobial peptide microbicides targeting HIV. Protein and Peptide Letters. 2005, v. 12, р. 41-47.
- Хаитов Р.М., Пинегин Б.В. Современные иммуномодуляторы, классификация, механизм действия. Рос. аллергол. журн. 2005, № 4, с. 30-43.
Supplementary files
